CompletedNot Applicable

Crustacean Allergy and Dust Mites Sensitization

Italy100 participantsStarted 2010-09

Plain-language summary

This study evaluates the diagnostic efficacy of CAP System (capsulated hydrophilic carrier polymer) for recombinant tropomyosin from shrimp extract in discriminating between subjects allergic to shrimp with CAP positive subjects allergic to mites, crustaceans asymptomatic but with a positive CAP to shrimp, to identify those at greatest risk of food reactions.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * males and females aged between 18 and 80 years; * Patients with clinical manifestations have been discovered and documented allergy to shrimp and / or mite in which both demonstrated IgE-mediated mechanism (CAP System for shrimp and / or mite positive); * patients with questionable symptoms to shellfish are tested for unleashing double-blind placebo-controlled trial with shrimp and when clinical manifestations are enrolled; * all patients with these characteristics will necessarily have to sign the informed consent for inclusion in the study. Exclusion Criteria: * Women who are pregnant; * patients chronically treated with antihistamines or steroids; * those who deny consent to participate.

What they're measuring

Evaluation of the ability of the CAP System for recombinant tropomyosin in identifying those most at risk of food reactions

Timeframe: One day

Trial details

NCT IDNCT01634737

SponsorNiguarda Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2011-11

View on ClinicalTrials.gov More Food Allergy trials